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model (ﬁ ve-year horizon, three-month cycles) evaluating NSAID treatment in OA, the
overall AE related costs and their constituents associated with celecoxib and ibuprofen 
treatment were quantiﬁ ed and compared. The individual costs (11 in total) were
aggregated to four categories relevant to OA treatment: (i) costs directly attributable
to clinically signiﬁ cant gastrointestinal (GI) AEs; (ii) costs directly attributable to dys-
pepsia; (iii) costs associated with myocardial infarction (MI); and (iv) co-medication
(mainly proton pump inhibitors) costs. The model, which has a health care perspective,
was populated with UK data and a discount rate of 3.5% per year was used. Except 
for the MI risks which were adjusted for age, all absolute and relative risks were taken 
from a meta-analysis in a recent NICE HTA report. Costs were aggregated to 1000 
patients on treatment. RESULTS: Although 9 of the 11 adverse event related individual 
costs were lower with celecoxib than ibuprofen treatment, the overall cost difference 
(a42,640 in favor of celecoxib) was attenuated by the relatively high MI related costs 
associated with celecoxib treatment (a92,734). CONCLUSIONS: Whilst the GI safety 
proﬁ le of celecoxib yields cost advantages, the MI costs associated with celecoxib 
treatment weakens the effect on overall adverse event related costs resulting from the
beneﬁ cial GI safety proﬁ le.
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OBJECTIVES: Eight million women and two million men are afﬂ icted with osteopo-
rosis in the United States. There are additional 34 million people exhibiting low bone
mass at risk for the development of osteoporosis. The purpose of this study was to
describe the drug utilization and spending trends for bisphosphonate and other alter-
native osteoporosis medications in the Medicaid program. METHODS: Using a ret-
rospective and descriptive study, Medicaid pharmacy claims data extracted from the
Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 regarding
quarterly number of prescriptions, units usage, reimbursement amount, and reim-
bursement per prescription for the oral bisphosphonates, injectable bisphosphonates, 
and alternative osteoporosis medications. Drugs were identiﬁ ed using their respective 
national drug codes (NDC). RESULTS: Risedronate accounted for 27% of all bisphos-
phonates prescriptions while alendronate accounted for the vast majority of bisphos-
phonate prescriptions with approximately 70% of the market over the 1991–2007 
timeframe. Both alendronate and risedronate together accounted for approximately
92% of all reimbursements for both oral and injectable bisphosphonates during the 
study period. Alendronate’s market share, as measured by total reimbursement, has 
been steadily declining from third quarter of 2004 to the third quarter of 2007, 
accounting for approximately 57% of total reimbursements, contrary to the roughly
83% of all reimbursements from the fourth quarter of 1996 to the second quarter of 
2004. CONCLUSIONS: Market share for the leading brand drugs has steadily
declined with the introduction of generic competition as measured by overall utiliza-
tion and total reimbursement, such as risedronate competing with alendronate in the 
bisphosphonate market and raloxifene competing with calcitonin-salmon in the alter-
native osteoporosis market. Examination of the Medicaid data also revealed a strident 
market shift in utilization following the fourth quarter of 2005, resulting from the
switching of dual eligibles from Medicaid to Medicare Part D.
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OBJECTIVES: To compare the traditionally used approach for fracture risk assess-
ment in cost-effectiveness analysis (CEA) compared to the use of FRAX models 
based on multiple individual clinical risk factors (CRFs) using the osteoporosis treat-
ment bazedoxifene. METHODS: In CEA of osteoporosis the fracture risk has tradi-
tionally been calculated with risk-adjustments based on age, bone mineral density
(BMD) and prior fracture. The treatment effect has been derived from clinical trials 
and the same efﬁ cacy has been assumed irrespective of the fracture risk of the popula-
tion. A novel approach to fracture risk assessment considers the contribution of 8 
individual CRFs on fracture risk and mortality using the FRAX-tool. The application 
of FRAX to clinical trial populations has shown that treatment efﬁ cacy increases
with higher fracture risk. The cost-effectiveness was estimated in a Markov cohort 
model with US data using a health care perspective. The CEA compared the osteopo-
rosis treatment bazedoxifene (BZA) to no treatment in women with a T-score for
femoral neck BMD of 2.5SD and previous fracture. Using the old approach BZA 
was set to reduce the risk of vertebral fracture by 42% based on the overall analysis 
of the phase III study. Using the FRAX-approach the vertebral fracture risk reduction
varied depending on pre-hoc fracture probability in the target population and was 
estimated at 59%. The relative risk of a vertebral fracture compared to the general
population was 3.96 and 1.82 with the old and FRAX-approach, respectively. 
RESULTS: The cost per QALY gained with bazedoxifene treatment was estimated at 
$54,712 using the old approach and $33,650 using the FRAX-approach. This is due
to differences in the assessment of fracture risk efﬁ cacy, fracture risk and mortality. 
CONCLUSIONS: The advent of more accurate assessment of fracture risk assessment
and its use as a determinant of efﬁ cacy has important consequences for CEA.
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OBJECTIVES: Knee osteoarthrosis is a multifactorial, progressive and incurable rheu-
matic ailment; most treatments look for a maximum recovery of mobility and func-
tionality of the knee joint, with a minimum risk possibility. Due to its high cost and 
invasive character, gonarthrosis surgical treatment is reserved, according to the clinical
practice guidance available in Mexico, for severe pain and joint functionality limita-
tion cases; deﬁ ned as knee osteoarthrosis present in IV degree, or functional class III
onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs.
intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. 
METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypotheti-
cal cohort behavior of patients with severe knee osteoarthrosis for a period of two 
years, from the perspective of the health service supplier. Costs were estimated using 
prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US 
dollar). RESULTS: With Hylan G-F 20, 94.6% of patients did not require surgery 
during the analysis period vs. 50%, in the case of those under intraarticular steroid 
treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular ste-
roids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 
and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as
dominant alternative. Different sensitivity analyses corroborate the dominance rela-
tionship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS:
Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment 
to withhold surgery in patients with severe knee osteoarthrosis.
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OBJECTIVES: To determine the cost-effectiveness of etanercept plus methotrexate
(MTX) versus rituximab plus MTX in the treatment of rheumatoid arthritis (RA)
patients from a payer’s perspective in Mexico. METHODS: A literature-based decision 
analytic model was developed to compare the cost and effectiveness of etanercept
25 mg twice-weeklyMTX versus rituximab 2 r 500 mg infusionMTX and ritux-
imab 2 r 1000 mg infusionMTX (labeled dosage) in RA patients with an inadequate
response to disease-modifying anti-rheumatic drugs. The primary measure of clinical
outcomes was based on remission (Disease Activity Score 28 joint count 2.6). The 
model incorporated major and minor infectious events, discontinuation due to inade-
quate efﬁ cacy or adverse event, and rituximab re-treatment within the one year time-
horizon. Data from clinical trials (TEMPO and SERENE) were used. Drug and 
resource-use costs were based on government-reported public costs. Sensitivity analy-
sis was conducted by varying efﬁ cacy and cost parameters by o 30%. RESULTS:
The annual total therapy cost for rituximab was MEX$74,543 (2 r 500 mg) 
and MEX$137,223 (2 r 1000 mg), and MEX$119,133 for etanercept. The incre-
mental cost-effectiveness ratio (ICER) of etanercept vs. rituximab 2 r 500 mg was 
MEX$201,581 per additional patient achieving remission. Etanercept was cost saving 
compared to rituximab 2 r 1000 mg. With a hypothetical budget of MEX$10,000,000
for rituximab or etanercept, the number of patients achieving remission would be 7
(2 r 500 mg) and 4 (2 r 1000 mg) for rituximab and 23 for etanercept. Sensitivity
analysis showed that etanercept continued to have more patients achieving remission 
than rituximab (for both dosage forms) even if drug cost and efﬁ cacy were varied o
30%, given a deﬁ ned budget. CONCLUSIONS: The results suggest that etanercept 
appears to be cost-effective compared to rituximab. For the labeled and commonly 
used rituximab dosage (2 r 1000 mg), etanercept appears to be a cost-saving alterna-
tive. These ﬁ ndings were robust for plausible ranges of effectiveness and drug acquisi-
tion costs.
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OBJECTIVES: Purpose of the study was to conduct a cost-efﬁ cacy analyses between 
three combinations of Tumor Necrosis Factor-Alpha agents used in treatment of 
rheumatoid arthritis. The study compared adalimumab plus methotrexate 
(ADALMTX), inﬂ iximab plus methotrexate (INFLMTX), etanercept plus metho-
trexate (ETANMTX), with methotrexate (MTX) monotherapy (control). METHODS:
The study was conducted from the patients’ perspective. Costs calculated for a period 
of one year included direct medical costs (drug acquisition costs, monitoring costs,
and adverse drug event costs) and indirect costs (estimated using human capital 
approach). All costs were calculated in 2007 dollars and adjusted using a discounting
factor of 3%. Outcome of therapeutic options was measured using the American 
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College of Rheumatology criteria for 20% improvement (ACR20 criteria). Data was
obtained from a comprehensive literature review using PubMed, Medline, and
Cochrane library. Efﬁ cacy values were obtained from published randomized clinical 
trials. A decision tree analyses was conducted followed by one-way and two-way 
sensitivity analyses. Costs and efﬁ cacy values associated with therapeutic options were 
varied in the sensitivity analyses. RESULTS: The probability of achieving ACR20
response for ETANMTX, ADALMTX, INFLMTX, and MTX were 85.5%, 
65.95%, 61.26%, and 39.94%, respectively. The probability of an adverse drug event 
occurrence for ETANMTX, ADALMTX, INFLMTX, and MTX were 14.0%, 
6.5%, 7.9%, and 9.5%, respectively. The analysis revealed that ETANMTX option 
was the most cost-efﬁ cacious, with an annual cost of $52,369 to the patient. The
annual cost savings with ETANMTX combination use would be $19,318. Annual
costs of ADALMTX, INFLMTX, and MTX monotherapy were $79,058, $68,932, 
and $67,071 respectively. Results were robust to both one-way and two-way analysis. 
CONCLUSIONS: Etanercept plus Methotrexate combination therapy was a better 
option based on the ACR 20 outcome measure considered. An analysis using real
world data and/or a prospective head-to-head comparison study could provide better 
conclusive evidence for decision-makers.
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OBJECTIVES: An observational study comparing risedronate to alendronate (REAL) 
in a subgroup of postmenopausal osteoporotic (PMO) women with prior fracture
demonstrated that treatment with risedronate reduced the incidence of hip fracture by
66% in the ﬁ rst year of treatment (Delmas, 2008). The objective of this analysis was 
to determine the cost-effectiveness of risedronate compared to alendronate at generic
pricing using these effectiveness data in a high risk PMO population in the U.S. 
METHODS: A validated Markov model of osteoporosis (Tosteson, 2001) was used 
to estimate the impact of therapy on hip fractures, costs, and quality-adjusted life
years (QALYs). The model simulated a cohort of 1000 women ages 65 with 
BMDa2.5 and a previous vertebral fracture, treated with risedronate or alendronate
for one year. Associated costs and QALYs were tracked for an additional two years 
in each arm. Hip fracture incidence and mortality rates, as well as drug (generic alen-
dronate 93.5% lower than risedronate) and hip fracture costs were extracted from
published literature. RESULTS: In a cohort of 1000 women treated with risedronate 
versus alendronate, the model predicted 25 fewer hip fractures and 8.41 additional 
QALYs, resulting in a cost savings of $330,378. Extrapolating to a population of PMO 
women with a prior vertebral fracture in the U.S. suggests that risedronate prevents
over 114,000 fractures in roughly 4.6 million women at cost savings of over $1,515 
million. A sensitivity analysis assuming treatment for 2 years and parity efﬁ cacy in
year 2 resulted in a cost per QALY gained for earlier fracture protection of $9925
(cost per fracture averted: $3419) when treating with risedronate versus alendronate
in the population 65. Risedronate remains cost-saving in the 80 population. CON-
CLUSIONS: Based on “real world” data this analysis suggests risedronate’s early
fracture protection results in favorable cost-effectiveness versus generic alendronate
despite its higher drug cost.
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OBJECTIVES: To determine and quantify the key drivers of cost-effectiveness in 
osteoarthritis (OA) treatment with traditional NSAIDs and COX-2 selective pharma-
ceuticals. METHODS: Cost effectiveness analysis (CEA) in OA treatment with tradi-
tional NSAIDs and COX-2 selective pharmaceuticals focus on side effects given the 
non-signiﬁ cant differences in efﬁ cacy (pain relief) among treatments. The most fre-
quently included side-effects and complications in OA CEA analysis are gastrointesti-
nal (GI) complications and myocardial infarction (MI). Given the concern about
broader cardiovascular (CV) risks associated with NSAID treatment, the scope of a
recently published Markov model (ﬁ ve-year horizon, three-month cycles, health care
perspective) was expanded to include four additional CV events (stroke, coronary
insufﬁ ciency, venous thromboembolism and angina). Two treatments priced at 1) the 
average of celecoxib and etoricoxib, and 2) ibuprofen were evaluated. The model was 
populated with UK data. Absolute and relative GI risks were derived from a recent 
NICE HTA report whereas absolute CV risks were assumed to equal the normal 
population risk and relative CV risks were taken from the literature. The model was 
used to determine the most important drivers of cost-effectiveness in OA treatment. 
This was done by evaluating the responsiveness of the ICER to a 1% change in the 
input variable of interest, controlling for changes in all other variables. RESULTS:
The ﬁ ve most inﬂ uential variables were (% impact on ICER resulting from 1% change
in the variable): Quality of life in arthritis (2.5%), relative risk of CV events (1.5%), 
relative risk of mild GI events (1.3%), price of the COX-2 pharmaceutical (1.3%) and 
quality of life in dyspepsia (0.7%). CONCLUSIONS: Whilst the most important cost-
effectiveness driver in OA treatment is overall quality of life changes, the analysis
indicate that there might be higher economic beneﬁ ts associated with decreasing CV 
risks rather than decreasing aspects of GI risk.
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OBJECTIVES: Injection site reactions (ISR) are the most common type of adverse 
event associated with the subcutaneous use of the tumor necrosis factor inhibitor 
(Anti-TNF) agents, etanercept (Enbrel) and adalimumab (Humira). The purpose of 
this study was to 1) investigate the incidence and characteristics of ISR, and 2) capture
the humanistic and economic consequences of ISR in patients who received etanercept
and/or adalimumab for rheumatoid arthritis (RA). METHODS: RA patients were 
identiﬁ ed through a query of outpatient claims with an ICD-9 code for RA and prac-
tice code for Jefferson Rheumatology Associates, Philadelphia, PA. Patients who met 
inclusion criteria of q18 years old and having received etanercept or adalimumab in
the past 3 years were administered a one-time observational survey developed by the 
investigators. RESULTS: The study included thirty patients, ﬁ ve of which had used
both adalimumab and etanercept. The overall prevalence of ISR was 56.3% (9
patients, n  16) for adalimumab and 84.2% (16 patients, n  19) for etanercept. 
Clinical characteristics of ISR included erythema (44.4%–68.8%), pruritus (44.4%–
68.8%), and swelling (33.3%–56.3%). Only one patient (3.3%) in the cohort was 
pre-medicated for ISR. Three patients in the adalimumab (n  9, 33.3%) and one 
patient in the etanercept group (n  16, 6.25%) called their physician when experienc-
ing a ﬁ rst-time ISR. Ice was the most common form of treatment for the ﬁ rst, typical, 
and worst incidence of ISR. No patients reported going to the ER, taking antihista-
mines, or using analgesics to treat ISR. Two patients (22.2%) and no patients discon-
tinued therapy due to ISR in the adalimumab and etanercept group, respectively. No
missed work-days were reported in either group due to ISR. CONCLUSIONS: ISR 
occurred in over half of the patient cases studied, and was largely characterized by 
erythema, pruritis, and swelling. Patient counseling about ISR is essential since self-
treatment is common and discontinuation may result.
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OBJECTIVES: Psoriatic arthritis (PsA) is an inﬂ ammatory arthritis occurring in about 
10–30% of the patients with psoriasis. Registration of highly effective but costly bio-
logical drugs for the treatment of PsA gave an extra impulse to economic evaluations
in rheumatology. There are no data on cost-of-illness of PsA neither from Hungary 
nor from countries with similar economic status (i.e. Poland, Slovakia and Czech 
Republic). The main goal of present study was to collect data on disease burden and 
costs of patients with PsA in Hungary. METHODS: A cross sectional questionnaire
survey of consecutive patients aged q18 years with diagnosis of PsA was conducted 
in 8 hospital based rheumatology outpatient centres in Hungary in 2008. Data were 
collected by rheumatologists during routine outpatient visits. Observed variables were 
demographic data, disease duration, disease activity score (DAS28), psoriasis area
severity index (PASI), drug use, the use of aids and devices, imaging, gastroscopy, 
outpatient visit, admissions to hospital, orthopaedic surgery, spa, physiotherapy, home 
care, transportation, non-reimbursed health care services, home remodelling and infor-
mal care. Data on PsA related reduction of working hours, sick leave and disability 
pension were collected also. RESULTS: A total of 183 patients were enrolled, of these, 
104 (57%) were women. The mean age of the sample was 50.3 (SD 12.9) years and 
the mean disease duration was 9.2 (9.2) years. The annual average direct, indirect and 
total costs were 2 670, 2 904 and 5 574 euros/patient/year in PsA, respectively. The 
main cost domains were the productivity losses due to work disability (49%) and the 
costs of biologic therapies (18%), with 2 742 (SD 4 920) and 1 008 (SD 4 134) 
euros/patient/year, respectively. CONCLUSIONS: Our study showed that the eco-
nomic burden of PsA is considerable in Hungary and provided a baseline to evaluate 
the economic effect of treatments in PsA.
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OBJECTIVES: Assess direct (medical and drug) and indirect (workloss) costs of 
osteoporotic patients with non-vertebral (NV) fractures. METHODS: Osteoporosis 
patients (ICD-9-CM code 733.0) were identiﬁ ed (1999–2006) from an employer
claims database (^8,000,000 privately-insured beneﬁ ciaries; ages 18–64) and the
Medicare Standard Analytic Files 5% sample (ages 65). Osteoporotic patients with 
NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib, or hip) were randomly 
matched on age, gender, employment status, and geography to osteoporotic controls. 
